Human papillomavirus vaccines: challenges to implementation
Suzanne M. GarlandDepartment of Microbiology and Infectious Diseases, Department of Microbiological Research, Royal Women’s Hospital, 132 Grattan St, Carlton, VIC 3053, Australia. Department of Obstetrics and Gynaecology, University of Melbourne, VIC, Australia. Email: suzanne.garland@rch.org.au
Sexual Health 3(2) 63-65 https://doi.org/10.1071/SH06018
Submitted: 14 March 2006 Accepted: 21 March 2006 Published: 26 May 2006
Abstract
Clinical trials for prophylactic human papillomavirus (HPV) vaccines have shown overwhelmingly positive results. It is expected that with good coverage of the vaccine, 70% of cervical cancers will be prevented, as will a proportion of other HPV-related anogenital diseases. Issues that will require careful consideration will include: whether males and females should be vaccinated; the durability of the immune response; the proportion of attributable disease to the HPV types targetted by the vaccines; and accessibility and cost of the vaccine. Central to an effective vaccination programme will be clear, concise and consistent educative messages regarding HPV not only to the lay public, but also the medical profession.
[1] Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347(21): 1645–51.
| Crossref | GoogleScholarGoogle Scholar | PubMed | [verified May 2006].
